Pinnacle Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57M Sell
61,937
-281
-0.5% -$285K 0.73% 27
2025
Q4
$66.9M Sell
62,218
-1,409
-2% -$1.35M 0.86% 21
2025
Q3
$48.5M Buy
63,627
+9,445
+17% +$7.03M 0.64% 31
2025
Q2
$42.2M Buy
54,182
+797
+1% +$619K 0.61% 34
2025
Q1
$44.1M Buy
53,385
+57
+0.1% +$47.4K 0.65% 29
2024
Q4
$41.2M Sell
53,328
-4,967
-9% -$4.11M 0.56% 35
2024
Q3
$34M Buy
58,295
+1,279
+2% +$1.15M 0.58% 37
2024
Q2
$51.6M Sell
57,016
-408
-0.7% -$326K 0.81% 24
2024
Q1
$44.7M Sell
57,424
-871
-1% -$620K 0.7% 31
2023
Q4
$34M Sell
58,295
-4,438
-7% -$2.59M 0.57% 37
2023
Q3
$33.7M Sell
62,733
-1,807
-3% -$931K 0.63% 33
2023
Q2
$30.3M Buy
64,540
+5,149
+9% +$2.16M 0.53% 47
2023
Q1
$20.4M Sell
59,391
-520
-0.9% -$175K 0.42% 65
2022
Q4
$21.9M Sell
59,911
-1,763
-3% -$625K 0.48% 56
2022
Q3
$19.9M Sell
61,674
-1,785
-3% -$566K 0.46% 56
2022
Q2
$20.6M Sell
63,459
-498
-0.8% -$149K 0.45% 60
2022
Q1
$18.3M Buy
63,957
+786
+1% +$202K 0.32% 92
2021
Q4
$17.4M Buy
63,171
+483
+0.8% +$122K 0.3% 100
2021
Q3
$14.5M Sell
62,688
-288
-0.5% -$71.1K 0.27% 108
2021
Q2
$14.5M Buy
62,976
+22,986
+57% +$4.62M 0.26% 112
2021
Q1
$7.47M Sell
39,990
-3,584
-8% -$701K 0.14% 165
2020
Q4
$7.36M Sell
43,574
-193
-0.4% -$28.8K 0.15% 153
2020
Q3
$6.48M Sell
43,767
-1,442
-3% -$223K 0.15% 155
2020
Q2
$7.42M Sell
45,209
-913
-2% -$140K 0.18% 133
2020
Q1
$6.4M Sell
46,122
-199
-0.4% -$27.3K 0.19% 131
2019
Q4
$6.09M Buy
46,321
+135
+0.3% +$15.6K 0.13% 179
2019
Q3
$5.17M Buy
46,186
+1,334
+3% +$149K 0.12% 195
2019
Q2
$4.97M Sell
44,852
-4,585
-9% -$540K 0.12% 204
2019
Q1
$6.42M Sell
49,437
-3,018
-6% -$367K 0.14% 174
2018
Q4
$6.07M Sell
52,455
-1,602
-3% -$179K 0.16% 166
2018
Q3
$5.8M Buy
54,057
+485
+0.9% +$48.5K 0.12% 191
2018
Q2
$4.57M Sell
53,572
-486
-0.9% -$39.9K 0.09% 220
2018
Q1
$4.18M Buy
54,058
+742
+1% +$59.7K 0.08% 231
2017
Q4
$4.5M Buy
53,316
+347
+0.7% +$29.5K 0.09% 219
2017
Q3
$4.53M Buy
52,969
+1,649
+3% +$135K 0.08% 219
2017
Q2
$4.22M Buy
51,320
+4,780
+10% +$390K 0.08% 222
2017
Q1
$3.91M Sell
46,540
-1,637
-3% -$131K 0.07% 236
2016
Q4
$3.54M Buy
48,177
+6,873
+17% +$512K 0.07% 244
2016
Q3
$3.31M Buy
41,304
+579
+1% +$46.3K 0.07% 244
2016
Q2
$3.21M Buy
40,725
+607
+2% +$45.7K 0.07% 245
2016
Q1
$2.89M Buy
40,118
+936
+2% +$70.8K 0.06% 247
2015
Q4
$3.3M Sell
39,182
-16,874
-30% -$1.4M 0.07% 234
2015
Q3
$4.69M Sell
56,056
-2,444
-4% -$206K 0.1% 194
2015
Q2
$4.88M Sell
58,500
-1,033
-2% -$78.7K 0.09% 202
2015
Q1
$4.33M Sell
59,533
-4,257
-7% -$303K 0.08% 210
2014
Q4
$4.4M Sell
63,790
-497
-0.8% -$33.5K 0.09% 208
2014
Q3
$4.17M Buy
64,287
+373
+0.6% +$23.6K 0.08% 209
2014
Q2
$3.97M Sell
63,914
-4,706
-7% -$281K 0.08% 210
2014
Q1
$4.04M Buy
68,620
+5,173
+8% +$289K 0.08% 200
2013
Q4
$3.24M Buy
63,447
+10,413
+20% +$521K 0.06% 228
2013
Q3
$2.67M Buy
53,034
+16,254
+44% +$851K 0.06% 246
2013
Q2
$1.81M Buy
+36,780
New +$2M 0.04% 279

Other funds holding LLY

Pinnacle Associates's LLY Position: Q1 2026 in Review

Pinnacle Associates reduced its Eli Lilly (LLY) stake by 0.45% in Q1 2026, selling an estimated $285K and leaving 61,937 shares worth $57M. The position accounts for 0.73% of the portfolio, ranked #27.

Pinnacle Associates first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $66.9M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Pinnacle Associates held 61,937 shares of Eli Lilly worth $57M as of Q1 2026.
  • Pinnacle Associates sold 281 Eli Lilly shares in Q1 2026, an estimated $285K.
  • Eli Lilly made up 0.73% of Pinnacle Associates's portfolio in Q1 2026, its #27 holding.
  • Pinnacle Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Pinnacle Associates's Eli Lilly position peaked at $66.9M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.